Virotex: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Virotex
Largest movements
- Current investments +€20,000
up €20,000 (+7.1%), from €280,000 to €300,000
- Deferred charges and accrued income -€5,442
down €5,442 (-81.9%), from €6,642 to €1,200
- Reserves +€17,924
up €17,924 (+6.5%), from €273,831 to €291,755
of which Distributable reserves: +€17,924
- Financial income -€5,763
down €5,763 (-73.2%), from €7,873 to €2,110
- Gross operating margin +€4,424
up €4,424 (+27.5%), from €16,075 to €20,500
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €339,443 | €357,340 | +€17,896 | +5.3% |
| Fixed assets | 21/28 | €39,011 | €39,011 | = | 0.0% |
| Tangible fixed assets | 22/27 | €38,391 | €38,391 | = | 0.0% |
| Land and buildings | 22 | €38,391 | €38,391 | = | 0.0% |
| Financial fixed assets | 28 | €620 | €620 | = | 0.0% |
| Current assets | 29/58 | €300,433 | €318,329 | +€17,896 | +6.0% |
| Amounts receivable within one year | 40/41 | €1,883 | €2,129 | +€246 | +13.1% |
| Trade receivables | 40 | €1,656 | €1,656 | = | 0.0% |
| Other amounts receivable | 41 | €227 | €473 | +€246 | +108.6% |
| Current investments | 50/53 | €280,000 | €300,000 | +€20,000 | +7.1% |
| Cash at bank and in hand | 54/58 | €11,908 | €15,000 | +€3,092 | +26.0% |
| Deferred charges and accrued income | 490/1 | €6,642 | €1,200 | -€5,442 | -81.9% |
| Total equity and liabilities | 10/49 | €339,443 | €357,340 | +€17,896 | +5.3% |
| Equity | 10/15 | €335,831 | €353,755 | +€17,924 | +5.3% |
| Contributions | 10/11 | €62,000 | €62,000 | = | 0.0% |
| Capital | 10 | €62,000 | €62,000 | = | 0.0% |
| Issued capital | 100 | €62,000 | €62,000 | = | 0.0% |
| Reserves | 13 | €273,831 | €291,755 | +€17,924 | +6.5% |
| Non-distributable reserves | 130/1 | €6,200 | €6,200 | = | 0.0% |
| Legal reserve | 130 | €6,200 | €6,200 | = | 0.0% |
| Tax-exempt reserves | 132 | €7,570 | €7,570 | = | 0.0% |
| Distributable reserves | 133 | €260,061 | €277,985 | +€17,924 | +6.9% |
| Amounts payable | 17/49 | €3,612 | €3,584 | -€28 | -0.8% |
| Amounts payable within one year | 42/48 | €3,612 | €3,584 | -€28 | -0.8% |
| Taxes, remuneration and social security | 45 | €28 | - | -€28 | |
| Taxes | 450/3 | €28 | - | -€28 | |
| Other amounts payable | 47/48 | €3,584 | €3,584 | = | 0.0% |
| Other operating charges | 640/8 | €2,637 | €2,718 | +€81 | +3.1% |
| Gross operating margin | 9900 | €16,075 | €20,500 | +€4,424 | +27.5% |
| Operating profit (loss) | 9901 | €13,438 | €17,782 | +€4,343 | +32.3% |
| Financial income | 75/76B | €7,873 | €2,110 | -€5,763 | -73.2% |
| Recurring financial income | 75 | €7,873 | €2,110 | -€5,763 | -73.2% |
| Financial charges | 65/66B | €294 | €175 | -€118 | -40.2% |
| Recurring financial charges | 65 | €294 | €175 | -€118 | -40.2% |
| Profit (loss) for the period before taxes | 9903 | €21,018 | €19,717 | -€1,301 | -6.2% |
| Income taxes | 67/77 | €1,911 | €1,792 | -€118 | -6.2% |
| Profit (loss) for the period | 9904 | €19,107 | €17,924 | -€1,183 | -6.2% |
| Profit (loss) for the period to be appropriated | 9905 | €19,107 | €17,924 | -€1,183 | -6.2% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 10 October 2026 via checked.be.